Preoperative Chemotherapy for Gastric Cancer: Personal Interventions and Precision Medicine

Table 1

Preoperative and perioperative chemotherapy in resectable GC.

Reference	Selection criteria	Experimental versus control group	Patients; ()	R0 resection; (%)	Survival rate; (%)
Songun et al. [9] and Hartgrink et al. [10]	T2–T4; M0; GC	versus surgery alone	27 versus 29	56 versus 62	32 versus 53 (5 years)
Cunningham et al. [5]	Resectable GC, GEJ, or lower esophagus	versus surgery alone	250 versus 253	74 versus 68	36 versus 23 (5 years)
Ychou et al. [11]	Resectable GC, GEJ, or lower esophagus	versus surgery alone	113 versus 111	84 versus 73	38 versus 24 (5 years)
Schuhmacher et al. [12]	Locally advanced GC; GEJ	versus surgery alone	72 versus 72	81.9 versus 66.7	72.7 versus 69.9 (2 years)
Oyama et al. [13]	Advanced GC with PAN metastasis	DCS + surgery versus surgery alone	16 versus 28	NS	93.8 versus 32.9 (2 years)
Kinoshita et al. [14]	Potentially resectable stage IV GC	DCS + surgery versus DCS	34 versus 23	NS	50.1 versus 0.0 (3 years)

GC: gastric cancer; GEJ: gastroesophageal junction; FAMTX: 5-fluorouracil, doxorubicin, and methotrexate; ECF: epirubicin, cisplatin, and fluorouracil; FP: fluorouracil and cisplatin; PFL: cisplatin, fluorouracil, and d-L-folinic acid; PAN: para-aortic lymph node; DCS: docetaxel, cisplatin, and S-1; NS: not stated.